Full Text View
Tabular View
No Study Results Posted
Related Studies
Nipple Aspiration, Ductal Lavage, and Duct Endoscopy For Diagnostic Assessment in Women Undergoing Surgery for Breast Cancer
This study is currently recruiting participants.
Study NCT00083018   Information provided by National Cancer Institute (NCI)
First Received: May 14, 2004   Last Updated: February 6, 2009   History of Changes

May 14, 2004
February 6, 2009
September 2003
 
  • Correlation of cell yields and morphology in ductal lavage with duct endoscopy appearances and findings [ Designated as safety issue: No ]
  • Sensitivity and specificity of ductal lavage with or without ductoscopy in detecting atypical cells [ Designated as safety issue: No ]
  • Comparison of cell yields vs final surgical pathology of the operative specimens [ Designated as safety issue: No ]
  • Correlation of cell yields and morphology in ductal lavage with duct endoscopy appearances and findings
  • Sensitivity and specificity of ductal lavage with or without ductoscopy in detecting atypical cells
  • Comparison of cell yields vs final surgical pathology of the operative specimens
Complete list of historical versions of study NCT00083018 on ClinicalTrials.gov Archive Site
 
 
 
Nipple Aspiration, Ductal Lavage, and Duct Endoscopy For Diagnostic Assessment in Women Undergoing Surgery for Breast Cancer
Evaluation Of The Role Of Nipple Aspiration, Ductal Lavage And Duct Endoscopy At The Time Of Surgery In Patients With Breast Cancer

RATIONALE: Diagnostic procedures, such as nipple aspiration, ductal lavage, and breast duct endoscopy, may help doctors detect and assess breast cancer cells early and plan more effective treatment.

PURPOSE: This phase II trial is studying how well nipple aspiration, ductal lavage, and duct endoscopy work in assessing cancer cells in women who are undergoing surgery for breast cancer.

OBJECTIVES:

Primary

  • Correlate the cell yield and morphology findings from ductal lavage with duct endoscopy findings and surgical pathology findings in women with breast cancer.
  • Determine the sensitivity and specificity of nipple aspiration, ductal lavage, and duct endoscopy in detecting established breast cancer in these patients.

Secondary

  • Compare the intraduct environment of cancer-involved ducts in the affected breast vs the ductal systems in the contralateral breast of these patients.
  • Perform immunohistochemical analysis (including estrogen receptor, progesterone receptor, HER2-neu receptor, epidermal growth factor receptor, p53, and proliferation marker expression) for markers potentially associated with breast cancer in these patients.
  • Determine potential molecular markers of malignancy by gene methylation, gene expression, and proteomics in these patients.
  • Compare the biochemistry and protein analysis of the intraductal fluid vs serum analysis in these patients.

OUTLINE: Patients undergo nipple aspiration, ductal lavage, and duct endoscopy under general anesthesia immediately before breast surgery. Fluid and tissue obtained are examined for tumor markers by immunohistochemistry. Candidate genes are analyzed by gene methylation, gene expression arrays, and proteomic profiling.

Patients are followed at 24 hours and at 1 week.

PROJECTED ACCRUAL: A total of 100 patients will be accrued for this study within 1 year.

Phase II
Interventional
Diagnostic
Breast Cancer
  • Genetic: cytogenetic analysis
  • Other: cytology specimen collection procedure
  • Other: laboratory biomarker analysis
  • Procedure: breast duct lavage
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Recruiting
100
 
 

DISEASE CHARACTERISTICS:

  • Diagnosis of breast cancer
  • No metastatic disease
  • No inflammatory breast cancer
  • Hormone receptor status:

    • Not specified

PATIENT CHARACTERISTICS:

Age

  • 18 and over

Sex

  • Female

Menopausal status

  • Not specified

Performance status

  • Not specified

Life expectancy

  • Not specified

Hematopoietic

  • Not specified

Hepatic

  • Not specified

Renal

  • Not specified

Other

  • No active infection or inflammation in the breast under study
  • No known allergy to eutectic mixture of local anesthetics (EMLA®) cream or lidocaine
  • No severe illness
  • Not unconscious
  • No mental illness or handicap
  • No nursing within the past 12 months
  • Not pregnant

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • Not specified

Chemotherapy

  • Not specified

Endocrine therapy

  • Not specified

Radiotherapy

  • Not specified

Surgery

  • No prior breast implantation on side of proposed lavage
  • No prior subareolar (e.g., papilloma resections, biopsies, or fine needle aspirations) or other surgery that may disrupt the ductal systems within 2 cm of the nipple

    • Biopsies and fine-needle aspirations > 2 cm from the nipple are allowed
Female
18 Years and older
No
 
United Kingdom
 
NCT00083018
 
CDR0000361760, RMNHS-2283, EU-20353
Royal Marsden - London
 
Study Chair: Gerald Gui, MD, MS, FRCS(Edin), FRCS(Eng) Royal Marsden - London
National Cancer Institute (NCI)
December 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP